Published in Oligonucleotides on June 01, 2009
Aptamers as therapeutics. Nat Rev Drug Discov (2010) 5.36
Effects of a high-fat diet on spontaneous metastasis of Lewis lung carcinoma in plasminogen activator inhibitor-1 deficient and wild-type mice. PLoS One (2014) 1.47
Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem Commun (Camb) (2012) 0.99
Aptamer-Drug Conjugates. Bioconjug Chem (2015) 0.89
Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding. RNA (2010) 0.85
Particle display: a quantitative screening method for generating high-affinity aptamers. Angew Chem Int Ed Engl (2014) 0.84
Characterisation of aptamer-target interactions by branched selection and high-throughput sequencing of SELEX pools. Nucleic Acids Res (2015) 0.79
Inhibition of PAI-1 antiproteolytic activity against tPA by RNA aptamers. Nucleic Acid Ther (2014) 0.79
Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis. PLoS One (2016) 0.76
Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. Nucleic Acid Ther (2011) 0.76
A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase. J Cell Mol Med (2016) 0.75
Aptamers: an emerging class of therapeutics. Annu Rev Med (2005) 4.15
Regulation of integrin function by the urokinase receptor. Science (1996) 3.56
The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature (1996) 3.34
Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology (2003) 2.47
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem (2005) 2.38
Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem (1985) 2.23
Plasminogen activation and cancer. Thromb Haemost (2005) 2.21
Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell (2001) 2.09
Structure and biological role of vitronectin. Annu Rev Cell Biol (1991) 2.02
Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost (2005) 1.96
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J (1995) 1.73
Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina (2002) 1.62
A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A (2005) 1.48
Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res (1996) 1.45
Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem (1998) 1.42
Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry (2001) 1.40
RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther (2008) 1.38
Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene (2003) 1.36
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation (2006) 1.35
Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem (1996) 1.31
Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost (2001) 1.23
Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost (2006) 1.21
The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem (1994) 1.18
Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants. J Biol Chem (1990) 1.16
siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol (2006) 1.16
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation (2008) 1.14
Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res (1997) 1.14
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost (2008) 1.13
Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost (1989) 1.11
Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost (2000) 1.09
Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J Biol Chem (2002) 1.04
Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Circulation (2001) 1.04
Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood (1987) 1.03
Antiprotease therapy in cancer: hot or not? Expert Opin Biol Ther (2006) 0.94
RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. FEBS Lett (2004) 0.93
Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. Bioessays (2007) 0.92
Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol (1991) 0.91
Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review). Int J Mol Med (2004) 0.90
Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem (2008) 0.89
Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem (1993) 0.88
Inhibition of PAI-1: a new anti-thrombotic approach. Curr Drug Targets Cardiovasc Haematol Disord (2002) 0.87
Role of exosites 1 and 2 in thrombin reaction with plasminogen activator inhibitor-1 in the absence and presence of cofactors. Biochemistry (1999) 0.84
Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Ther (2007) 0.84
Distortion of the catalytic domain of tissue-type plasminogen activator by plasminogen activator inhibitor-1 coincides with the formation of stable serpin-proteinase complexes. J Biol Chem (2003) 0.83
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Aptamers: an emerging class of therapeutics. Annu Rev Med (2005) 4.15
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med (2008) 3.64
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest (2003) 3.41
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
RNA aptamers as reversible antagonists of coagulation factor IXa. Nature (2002) 2.73
In vivo activity of nuclease-resistant siRNAs. RNA (2004) 2.33
Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol (2004) 2.18
Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet (2002) 2.02
Development of universal antidotes to control aptamer activity. Nat Med (2009) 1.93
Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF. J Biol Chem (2002) 1.81
A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics. Blood (2005) 1.81
Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J (2006) 1.66
Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation (2008) 1.62
Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest (2002) 1.44
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol (2008) 1.42
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest (2003) 1.42
RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther (2008) 1.38
In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol (2009) 1.36
Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation (2002) 1.34
Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci U S A (2003) 1.32
Crystal structure of an RNA aptamer bound to thrombin. RNA (2008) 1.32
A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol (2005) 1.31
Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1alpha, and C/EBPalpha. FASEB J (2006) 1.24
A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol (2008) 1.24
Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest (2009) 1.22
Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J Neurochem (2008) 1.21
Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides (2007) 1.20
Proteomic analysis of the Vibrio cholerae type II secretome reveals new proteins, including three related serine proteases. J Biol Chem (2011) 1.20
RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther (2007) 1.14
Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des (2003) 1.14
New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system. Exp Biol Med (Maywood) (2004) 1.14
A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther (2006) 1.13
Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem (2007) 1.09
H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity. Nucleic Acids Res (2006) 1.09
Functional repair of a mutant chloride channel using a trans-splicing ribozyme. J Clin Invest (2002) 1.07
Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain (2003) 1.07
Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci STKE (2003) 1.06
Optimizing aptamer activity for gene therapy applications using expression cassette SELEX. Mol Ther (2002) 1.06
Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol Chem (2009) 1.05
Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J Surg Res (2007) 1.05
Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci U S A (2012) 1.05
Acyl-enzyme complexes between tissue-type plasminogen activator and neuroserpin are short-lived in vitro. J Biol Chem (2002) 1.04
The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain (2012) 1.04
Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system. Thromb Haemost (2004) 1.04
Progressive ankylosis (Ank) protein is expressed by neurons and Ank immunohistochemical reactivity is increased by limbic seizures. Lab Invest (2003) 1.03
Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. J Neurosci (2009) 1.02
Conservation of critical functional domains in murine plasminogen activator inhibitor-1. J Biol Chem (2004) 1.02
PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury. J Pathol (2012) 1.02
Low density lipoprotein receptor-related protein-1 (LRP1) regulates thrombospondin-2 (TSP2) enhancement of Notch3 signaling. J Biol Chem (2010) 1.01
Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc Natl Acad Sci U S A (2007) 1.01
Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem Biophys Res Commun (2005) 1.00
Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing. Am J Pathol (2006) 1.00
The potential of aptamers as anticoagulants. Trends Cardiovasc Med (2005) 1.00
Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system? Trends Cardiovasc Med (2004) 0.99
Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. RNA (2009) 0.98
Nucleic acid-binding polymers as anti-inflammatory agents. Proc Natl Acad Sci U S A (2011) 0.98
Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system. Thromb Haemost (2004) 0.97
Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. J Vasc Surg (2011) 0.97
Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes. RNA (2003) 0.97
Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Mol Ther (2004) 0.96
Mouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes. J Biol Chem (2004) 0.96
Notch signaling in cancer stem cells. Adv Exp Med Biol (2012) 0.95
An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. J Biol Chem (2009) 0.95
The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin. J Biol Chem (2007) 0.95
Using 5'-PTMs to repair mutant beta-globin transcripts. RNA (2007) 0.94
A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis. J Biol Chem (2005) 0.94
Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis. Am J Physiol Renal Physiol (2009) 0.94
The low density lipoprotein receptor-related protein modulates protease activity in the brain by mediating the cellular internalization of both neuroserpin and neuroserpin-tissue-type plasminogen activator complexes. J Biol Chem (2003) 0.94
Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr Drug Targets (2007) 0.93
Plasminogen activator inhibitor-1 mitigates brain injury in a rat model of infection-sensitized neonatal hypoxia-ischemia. Cereb Cortex (2012) 0.93
RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. FEBS Lett (2004) 0.93
A chemical genetic screen for modulators of asymmetrical 2,2'-dimeric naphthoquinones cytotoxicity in yeast. PLoS One (2010) 0.92
Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. J Clin Invest (2012) 0.92
Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands. J Biol Chem (2008) 0.91
NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis. Biochem Biophys Res Commun (2007) 0.91
Sequences within domain II of the urokinase receptor critical for differential ligand recognition. J Biol Chem (2003) 0.90
The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood (2011) 0.90
Ribozyme-mediated revision of RNA and DNA. J Clin Invest (2003) 0.90
Aptamers in immunotherapy. Hum Gene Ther (2008) 0.89
Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia. Arterioscler Thromb Vasc Biol (2009) 0.89
PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. Breast Cancer Res (2008) 0.88
Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther (2012) 0.88
Tissue factor and obesity, a two-way street. Nat Med (2011) 0.88
Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Ther (2012) 0.87
Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1. J Biol Chem (2010) 0.87
Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology (2008) 0.87
Identification of a novel targeting sequence for regulated secretion in the serine protease inhibitor neuroserpin. Biochem J (2007) 0.87
Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function. J Biol Chem (2003) 0.87
Retargeting mobile group II introns to repair mutant genes. Mol Ther (2005) 0.86
Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures. Nanomedicine (2011) 0.85
Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. Nucleic Acid Ther (2012) 0.85
Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. J Cardiovasc Transl Res (2010) 0.84
Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors. J Biol Chem (2004) 0.83
Heparin cofactor II: discovery, properties, and role in controlling vascular homeostasis. Semin Thromb Hemost (2011) 0.83
In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells. Mol Ther (2007) 0.83
Characterization of recombinant human protein C inhibitor expressed in Escherichia coli. Biochim Biophys Acta (2005) 0.83
Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking. J Neurochem (2008) 0.83